Work

Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies

Year: 2021

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-021-01175-6

Authors: Joleen M. Hubbard, Jun Yin, Erin L. Schenk, Rui Qin, Joel M. Reid, Carrie Strand, Jack Fiskum, Michael Menefee, Grace Lin, L. Austin Doyle, Percy Ivy, Charles Erlichman, Alex Adjei, Paul Haluska, Brian A. Costello

Institutions: Mayo Clinic, University of Colorado Anschutz, United States Department of Veterans Affairs, Washington DC VA Medical Center, National Institutes of Health, National Cancer Institute, Bristol-Myers Squibb (United States)

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis, Phase I Clinical Trials of Anticancer Agents, Mayo Clinic Comprehensive Cancer Center Support Grant, Paul Calabresi Award in Clinical Oncology Research

OpenAlex ID: W3199530807

FWCI: 0.157

Cites: 56

Cited by: 3

Related to: 10